Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:HCM NASDAQ:MOR NASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$7.29+0.5%$6.87$4.25▼$9.85$2.70B0.482.64 million shs2.78 million shsHCMHUTCHMED$17.93+9.5%$16.42$11.51▼$21.50$3.11B0.4580,026 shs81,596 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AVALNValneva$8.96-2.4%$8.29$3.62▼$12.25$774.23M1.7970,327 shs31,970 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos+1.47%+0.62%+3.64%+20.70%+13.70%HCMHUTCHMED+4.20%+10.31%+6.71%-3.14%-2.62%MORMorphoSys0.00%0.00%0.00%0.00%0.00%VALNValneva+1.32%+3.85%-2.34%+52.75%+31.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$7.29+0.5%$6.87$4.25▼$9.85$2.70B0.482.64 million shs2.78 million shsHCMHUTCHMED$17.93+9.5%$16.42$11.51▼$21.50$3.11B0.4580,026 shs81,596 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AVALNValneva$8.96-2.4%$8.29$3.62▼$12.25$774.23M1.7970,327 shs31,970 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos+1.47%+0.62%+3.64%+20.70%+13.70%HCMHUTCHMED+4.20%+10.31%+6.71%-3.14%-2.62%MORMorphoSys0.00%0.00%0.00%0.00%0.00%VALNValneva+1.32%+3.85%-2.34%+52.75%+31.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 2.00Hold$9.0023.54% UpsideHCMHUTCHMED 2.33Hold$28.0056.21% UpsideMORMorphoSys 0.00N/AN/AN/AVALNValneva 3.00Buy$15.0067.34% UpsideCurrent Analyst Ratings BreakdownLatest VALN, MOR, HCM, and BHC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025HCMHUTCHMEDZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/8/2025VALNValnevaGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$14.00 ➝ $13.008/25/2025VALNValnevaJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$14.008/25/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/19/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.008/11/2025HCMHUTCHMEDZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/22/2025HCMHUTCHMEDBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $28.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$9.63B0.28$7.92 per share0.92($0.89) per share-8.19HCMHUTCHMED$602.20M5.19$0.33 per share54.69$4.43 per share4.05MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17VALNValneva$183.52M4.20$0.10 per share92.72$2.41 per share3.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos-$46M$0.2628.051.56N/A0.99%-852.36%5.25%10/29/2025 (Estimated)HCMHUTCHMED$37.73MN/A0.0012.28N/AN/AN/AN/AN/AMORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/AVALNValneva-$13.25M-$0.98N/AN/AN/A-33.87%-34.78%-13.43%11/6/2025 (Estimated)Latest VALN, MOR, HCM, and BHC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025VALNValneva-$0.27-$0.16+$0.11-$0.16$46.28 million$54.84 million7/30/2025Q2 2025BHCBausch Health Cos$0.97$0.90-$0.07$0.40$2.47 billion$2.57 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health Cos141.901.310.98HCMHUTCHMED0.054.654.51MORMorphoSys4.981.381.38VALNValneva0.662.271.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%HCMHUTCHMED8.82%MORMorphoSys18.38%VALNValneva11.39%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos19.97%HCMHUTCHMED3.60%MORMorphoSys0.05%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,700370.35 million296.39 millionOptionableHCMHUTCHMED1,811174.42 million168.14 millionNot OptionableMORMorphoSys730150.62 million150.55 millionNot OptionableVALNValneva70085.93 million73.12 millionNot OptionableVALN, MOR, HCM, and BHC HeadlinesRecent News About These CompaniesValneva Scotland makes strides toward £10K fundraising goal in support of charity partner Team JakSeptember 12 at 10:26 AM | msn.comVALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the FirmSeptember 11 at 5:16 PM | globenewswire.comValneva (NASDAQ:VALN) Stock Price Up 5.6% - Should You Buy?September 11 at 1:12 PM | marketbeat.comLevi & Korsinsky Launches Fraud Investigation on Behalf of Valneva SE (VALN) ShareholdersSeptember 10 at 6:46 PM | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNSeptember 10 at 2:21 PM | globenewswire.comValneva (NASDAQ:VALN) Price Target Lowered to $13.00 at GuggenheimSeptember 10 at 9:59 AM | marketbeat.comValneva (NASDAQ:VALN) Price Target Cut to $13.00 by Analysts at GuggenheimSeptember 10 at 2:49 AM | americanbankingnews.comA Lyme Disease Vaccine’s Final Test Results Could Appear By Yearend.September 9 at 11:49 PM | msn.comValneva price target lowered to $13 from $14 at GuggenheimSeptember 9 at 2:55 AM | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNSeptember 8, 2025 | prnewswire.comShort Interest in Valneva SE Sponsored ADR (NASDAQ:VALN) Expands By 64.6%September 8, 2025 | marketbeat.comValneva (NASDAQ:VALN) Rating Increased to Hold at Wall Street ZenSeptember 8, 2025 | marketbeat.comValneva (NASDAQ:VALN) Raised to Hold at Wall Street ZenSeptember 8, 2025 | americanbankingnews.comValneva (NASDAQ:VALN) Trading Up 5% - Here's WhySeptember 5, 2025 | marketbeat.comVALNEVA Declaration of shares and voting rights: August 31, 2025September 5, 2025 | finance.yahoo.comVALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the FirmSeptember 4, 2025 | globenewswire.comValneva (NASDAQ:VALN) Shares Gap Down - Here's What HappenedSeptember 4, 2025 | marketbeat.comValneva Reports Positive Phase 2 Results for Lyme Disease VaccineSeptember 3, 2025 | msn.comPfizer, Valneva boosted by updated vaccine data ahead of moment in the Lyme-lightSeptember 3, 2025 | fiercebiotech.comFValneva Shares Rise on Lyme Disease Vaccine Study DataSeptember 3, 2025 | marketwatch.comValneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine CandidateSeptember 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMongoDB Roars Back to Life: It’s Not Too Late to Buy MoreBy Thomas Hughes | August 27, 2025TJX Stock Price Hits Fresh High, Signals More Highs to FollowBy Thomas Hughes | August 22, 2025Alphabet’s Breakout Potential: From Laggard to AI LeaderBy Ryan Hasson | August 22, 2025Eyes on the Sky: AST SpaceMobile Prepares for Commercial LaunchBy Jordan Chussler | September 8, 20253 Undervalued Stocks Analysts Are Loving Right Now—Should You?By Gabriel Osorio-Mazilli | August 27, 2025VALN, MOR, HCM, and BHC Company DescriptionsBausch Health Cos NYSE:BHC$7.28 +0.04 (+0.48%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.HUTCHMED NASDAQ:HCM$17.92 +1.56 (+9.50%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 09/11/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Valneva NASDAQ:VALN$8.96 -0.22 (-2.35%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
